/stocks — the workspaceLOADING
All ANTX SEC filings, by type → · Earnings date & implied move · Search inside filings
AN2 Therapeutics, Inc. (ANTX) is a pharmaceutical preparations company. 10 insider Form 4 filings in the last 90 days. Next earnings projected around 2026-11-11 from ANTX's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
What’s behind ANTX’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
End-of-day bars · delayed, not real-time · data: Databento · studies computed in your browser from these barsCharting by TradingView Lightweight Charts™
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from ANTX’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
Not reported in XBRL for this filer.
A plain-English read on ANTX plus an auto-SWOT — built from ANTX's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate ANTX using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Has ANTX been issuing shares? Offering history →
↓ Download the fiscal-year statement table: XLSX · CSV · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
As filed. We do not recategorize line items. Each chart plots one XBRL concept exactly as ANTX tagged it: net income us-gaap:NetIncomeLoss, EPS us-gaap:EarningsPerShareDiluted, period by period; a period the company did not tag on its own is left out, not estimated. A figure that disagrees with the filing is a bug in our extraction, not a policy, and we fix it: report a mismatch.
None of the 5 estimators could run on ANTX's filings.
One estimator is a point estimate, not a range, so no band and no valuation label are published for ANTX. Below is everything that was checked, so the refusal can be read rather than taken on trust.
Nothing produced a value.
No fiscal year of price history was on record; the historical multiples need 5. No sector peer set is priced for ANTX, so sector medians could not fill the gaps.
Every refusal recorded for ANTX → · How often we decline, and why →
No lawmaker has disclosed a trade in ANTX under the STOCK Act.
Projected from ANTX's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentANTX files or announces.
ANTX has sold off after 4 of its last 6 earnings reports.
Each figure is one earnings reaction — how much ANTX moved from the closing price the day before a report to the close the day after. Based on its last 6 reports.
Earnings reactions have been moderate.
ANTX has traded lower after most recent earnings releases.
A more typical earnings reaction has been approximately ±5.0%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-08-11 | +6.3% |
| 2026-05-11 | -4.3% |
| 2026-03-17 | -1.5% |
| 2025-11-12 | -5.8% |
| 2025-03-25 | +0.7% |
| 2024-11-13 | -5.7% |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
No tracked institution reported a position in ANTX in the latest 13F round.
Every registered fund files its complete portfolio with the SEC. These weights come from those filings, so each one carries the period it describes. Holdings are quarterly and filed in arrears — the figures below are as of 2026-06-30, not today.
| Fund | Weight | As of |
|---|---|---|
| IWM iShares Russell 2000 ETF | <0.01% | 2026-06-30 |
| VTI Vanguard Total Stock Market ETF | <0.01% | 2026-06-30 |
Drawn from 39 large US equity funds we scan, not every fund in existence, so a missing fund means we do not scan it rather than that it holds none. Holdings are joined to tickers by issuer name, which does not resolve every position; what that misses is published.
Head office: Menlo Park, California, United States · the company’s charter and its head office are in different states.
Source: the cover page of AN2 Therapeutics, Inc.’s 10-Q filed 2026-08-11, on EDGAR. Filings checked 2026-10-26. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works
Of 6 sales in the last ~6 months, 3 were filed with the Rule 10b5-1 box checked, set up in advance under a written trading plan; 3 were filed without it.
| Readnour Robin ShaneDirector | SELLplan | $7K | view → |
| Readnour Robin ShaneDirector | SELLplan | $97K | view → |
| Williams Sarah JoannePrincipal Accounting Officer | SELL | $2K | view → |
| FitzPatrick Margaret MDirector | BUY | $12K | view → |
| Readnour Robin ShaneDirector | SELLplan | $213K | view → |
| Eizen Joshua MSee Remarks | SELL | $25K | view → |
| Williams Sarah JoannePrincipal Accounting Officer | SELL | $1K | view → |
2 of the 2 checks that ran found nothing new for ANTX. 2 could not run.
Each event check looks back 30 days from the date its own source was stored, read or generated, never from the date this page was built. A check that finds nothing is a measurement of that window, not a forecast, and a check that cannot be dated does not make the claim at all.
From SEC Form 4 and 13F filings. Both are backward-looking disclosures on different reporting clocks, and neither predicts price. Educational information only — not investment advice.